Valeant Pharmaceuticals VRX +4.44% is planning on paying its top brass multi-million dollar bonuses as a reward for sticking with the embattled drugmaker through an accounting scandal, numerous regulatory investigations, and criticism in the Senate and House of Representatives on its strategy of acquiring off-patent drugs and dramatically increasing their prices.
Late on Monday, Valeant disclosed that it will pay chief financial officer Robert L. Rosiello, and executives Dr. Ari Kellen and Anne C. Whitaker $1 million retention bonuses, paid in three tranches through the course of 2016. These executives will also receive so-called “special equity awards” of $2.8 million, $3.8 million and $1.25 million, respectively, in the form of restricted stock units that vest over 18 months.
Late on Monday, Valeant disclosed that it will pay chief financial officer Robert L. Rosiello, and executives Dr. Ari Kellen and Anne C. Whitaker $1 million retention bonuses, paid in three tranches through the course of 2016. These executives will also receive so-called “special equity awards” of $2.8 million, $3.8 million and $1.25 million, respectively, in the form of restricted stock units that vest over 18 months.
